Expectations and Concerns Towards New Extended Half-Life (EHL) Products - Results of Surveys Among Haemophilia Patients from the Dach Region

被引：0
|
作者：
von Mackensen, Sylvia [1 ]
Kalnins, Werner [2 ]
Lino, Hostettler [3 ]
Joerg, Krucker [3 ]
Albisetti, Manuela [4 ,5 ]
Weiss, Josef [6 ]
Pabinger, Ingrid [7 ]
Oldenburg, Johannes [8 ]
机构：
[1] Univ Med Ctr Hamburg Eppendorf, Inst Med Psychol, Hamburg-Eppendorf, Germany
[2] German Haemophilia Soc DHG, Hamburg, Germany
[3] Swiss Hemophilia Assoc SHG, Altstatten, Switzerland
[4] Swiss Hemophilia Network SHN, Zurich, Switzerland
[5] Univ Childrens Hosp, Dept Hematol, Zurich, Switzerland
[6] Austrian Hemophilia Soc OHG, Vienna, Austria
[7] Med Univ Vienna, Dept Med I, Vienna, Austria
[8] Univ Clin Bonn, Inst Expt Haematol & Transfus Med, Bonn, Germany
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 46 条
  • [31] Could effective iodine-131 half-life be extended by lithium carbonate in Graves' disease patients: Results from a retrospective analysis
    Gao, Xuemei
    Wu, Binbin
    Zhou, Qian
    Liu, Yan
    Wang, Ruihua
    BIOMOLECULES AND BIOMEDICINE, 2024, 24 (06): : 1711 - 1716
  • [32] FVIII post infusion monitoring survey: Results and analysis of extended half-life (EHL) FVIII/FIX products and laboratory performance for the external quality control assessment programmes of international external quality assessment scheme (IEQAS)
    Williams, Anna
    Kitchen, Dianne
    Reily-Stitt, Chris
    Jennings, Ian
    Kitchen, Steve
    HAEMOPHILIA, 2024, 30 : 82 - 83
  • [33] Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials
    Tiede, A.
    Abdul-Karim, F.
    Carcao, M.
    Persson, P.
    Clausen, W. H. O.
    Kearney, S.
    Matsushita, T.
    Negrier, C.
    Oldenburg, J.
    Santagostino, E.
    Young, G.
    HAEMOPHILIA, 2017, 23 (04) : 547 - 555
  • [34] An extended terminal half-life for darbepoetin alfa - Results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis
    Padhi, D
    Ni, LY
    Cooke, B
    Marino, R
    Jang, G
    CLINICAL PHARMACOKINETICS, 2006, 45 (05) : 503 - 510
  • [35] An extended terminal half-life for Aranesp® (darbepoetin alfa):: Results from a single-dose pharmacokinetic (PK) study in patients with chronic kidney disease (CKD)
    Padhi, D
    Jang, G
    Smith, B
    Marbury, T
    Cooke, B
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 : V255 - V255
  • [36] Revised terminal half-life of nonacog alfa as derived from extended sampling data: A real-world study involving 64 haemophilia B patients on nonacog alfa regular prophylaxis
    Tardy, Brigitte
    Lambert, Thierry
    Chamouni, Pierre
    Montmartin, Aurelie
    Trossaert, Marc
    Claeyssens, Segolene
    Berger, Claire
    Ardillon, Laurent
    Gay, Valerie
    Delavenne, Xavier
    Harroche, Annie
    Chelle, Pierre
    HAEMOPHILIA, 2022, 28 (04) : 542 - 547
  • [37] LONG-TERM OUTCOMES OF PREVIOUSLY-TREATED ADULT AND ADOLESCENT PATIENTS WITH SEVERE HAEMOPHILIA A RECEIVING PROPHYLAXIS WITH EXTENDED HALF-LIFE FVIII TREATMENTS: AN ECONOMIC ANALYSIS FROM A UK PERSPECTIVE
    Benson, G.
    Morton, T.
    Thomas, H.
    Lee, X. Y.
    VALUE IN HEALTH, 2020, 23 : S696 - S696
  • [38] Perioperative haemostasis with full-length, PEGylated, recombinant factor VIII with extended half-life (rurioctocog alfa pegol) in patients with haemophilia A: Final results of a multicentre, single-arm phase III trial
    Gruppo, Ralph
    Lopez-Fernandez, Maria-Fernanda
    Wynn, Tung T.
    Engl, Werner
    Sharkhawy, Marlies
    Tangada, Srilatha
    HAEMOPHILIA, 2019, 25 (05) : 773 - 781
  • [39] Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated adult, adolescent, and paediatric patients with haemophilia B - results from two phase 3 trials
    Abdul-Karim, Faraizah
    Carcao, Manuel
    Persson, Paula
    Clausen, Wan Hui Ong
    Kearney, Susan
    Matsushita, Tadashi
    Negrier, Claude
    Oldenburg, Johannes
    Santagostino, Elena
    Young, Guy
    HAEMOPHILIA, 2016, 22 : 100 - 100
  • [40] REAL-WORLD SPECIALTY PHARMACY DISPENSATION AND EXPENDITURES ASSOCIATED WITH STANDARD AND EXTENDED HALF-LIFE RECOMBINANT FACTOR IX PRODUCTS AMONG HEMOPHILIA B PATIENTS RECEIVING ON-DEMAND REGIMENS
    Fogarty, Patrick F.
    Alvir, Jose
    Chhabra, Amit
    McDonald, Margaret
    Tortella, Bartholomew J.
    Pleil, Andreas M.
    Spurden, Dean
    AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (09) : E19 - E20
12345